NCT01645735 - Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Infections

Interventions

DRUG

Ceftaroline fosamil

Ceftaroline fosamil 600 mg IV over 60 minutes q8h; treatment duration 5 to 14 days

DRUG

Ceftriaxone plus vancomycin

Ceftriaxone 2g IV over 30 minutes q24h plus vancomycin 15 mg/kg IV q12h initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days

Trial Locations (31)

3233

Investigational Site, Mátraháza

32720

Investigational Site, DeLand

43215

Investigational Site, Columbus

45801

Investigational Site, Lima

48073

Investigational Site, Royal Oak

49059

Investigational Site, Dnipropetrovsk

55145

Investigational Site, Minneapolis

60611

Investigational Site, Chicago

61115

Investigational Site, Kharkiv

63110

Investigational Site, St Louis

66012

Investigational Site, Kansas City

68131

Investigational Site, Omaha

69035

Investigational Site, Zaporizhzhya

73104

Investigational Site, Oklahoma City

76018

Investigational Site, Ivano-Frankivsik

85008

Investigational Site, Phoenix

91342

Investigational Site, Sylmar

109240

Investigational Site, Moscow

150003

Investigational Site, Yaroslavl

196247

Investigational Site, Saint Petersburg

200515

Investigational Site, Craiova

700115

Investigational Site, Iași

03246

Investigational Site, Laconia

0144

Investigational Site, Tbilisi

90-153

Investigational Site, Lodz

20-954

Investigational Site, Lublin

43-365

Investigational Site, Wilkowice-Bystra

030303

Investigational Site, Bucharest

03010

Investigational Site, Alicante

08304

Investigational Site, Barcelona

03680

Investigational Site, Kyiv